ORIENTBIO Inc. (002630) — Cash Flow-to-Debt Ratio
ORIENTBIO Inc. (002630) has a Cash Flow-to-Debt Ratio of 0.14x as of December 2025, meaning its operating cash flow of ₩1.77 Billion could theoretically repay 0% of its total liabilities (₩12.64 Billion) in one year. See ORIENTBIO Inc. (002630) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ORIENTBIO Inc. Cash Flow-to-Debt Ratio (2007–2025)
Historical debt coverage capacity for ORIENTBIO Inc. across 16 annual periods. For the full cash flow conversion analysis, see cash flow conversion of ORIENTBIO Inc..
Annual Cash Flow-to-Debt Ratio for ORIENTBIO Inc. (2007–2025)
Year-by-year debt coverage analysis for ORIENTBIO Inc.. Check ORIENTBIO Inc. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | ₩752.29 Million | ₩12.94 Billion | ▼ -81.6% |
| 2024 | 0.32x | ₩3.76 Billion | ₩11.89 Billion | ▲ +163.0% |
| 2023 | 0.12x | ₩1.16 Billion | ₩9.66 Billion | ▲ +11.2% |
| 2022 | 0.11x | ₩2.35 Billion | ₩21.76 Billion | ▼ -71.6% |
| 2021 | 0.38x | ₩8.74 Billion | ₩22.97 Billion | ▲ +296.3% |
| 2020 | -0.19x | ₩-3.90 Billion | ₩20.14 Billion | ▲ +64.0% |
| 2019 | -0.54x | ₩-11.54 Billion | ₩21.44 Billion | ▼ -2913.4% |
| 2018 | -0.02x | ₩-1.97 Billion | ₩110.11 Billion | ▲ +73.9% |
| 2017 | -0.07x | ₩-5.11 Billion | ₩74.68 Billion | ▼ -732.3% |
| 2016 | 0.01x | ₩912.43 Million | ₩84.35 Billion | ▼ -45.1% |
| 2015 | 0.02x | ₩1.60 Billion | ₩81.42 Billion | ▼ -29.4% |
| 2014 | 0.03x | ₩2.17 Billion | ₩77.78 Billion | ▼ -59.5% |
| 2013 | 0.07x | ₩5.09 Billion | ₩73.95 Billion | ▼ -57.2% |
| 2011 | 0.16x | ₩3.11 Billion | ₩19.38 Billion | ▼ -26.9% |
| 2010 | 0.22x | ₩9.35 Billion | ₩42.55 Billion | ▲ +305.7% |
| 2007 | 0.05x | ₩1.52 Billion | ₩28.02 Billion | — |